TrianglePUBLICATIONS · 24006085
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Cancer
- Publication date
- 2013 Nov 15
- First author
- O'Hear C
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- O'Hear C
- type
- Author
- name
- Inaba H
- type
- Author
- name
- Pounds S
- type
- Author
- name
- Shi L
- type
- Author
- name
- Dahl G
- type
- Author
- name
- Bowman WP
- type
- Author
- name
- Taub JW
- type
- Author
- name
- Pui CH
- type
- Author
- name
- Ribeiro RC
- type
- Author
- name
- Coustan-Smith E
- type
- Author
- name
- Campana D
- type
- Author
- name
- Rubnitz JE
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- O'Hear C
- type
- Author
- name
- Inaba H
- type
- Author
- name
- Pounds S
- type
- Author
- name
- Shi L
- type
- Author
- name
- Dahl G
- type
- Author
- name
- Bowman WP
- type
- Author
- name
- Taub JW
- type
- Author
- name
- Pui CH
- type
- Author
- name
- Ribeiro RC
- type
- Author
- name
- Coustan-Smith E
- type
- Author
- name
- Campana D
- type
- Author
- name
- Rubnitz JE
- type
- Author
- bibliography ids
- nci-bib-66a0a791d77e7f59243e0750
- book metadata
- content sha256
- b6aa87513ba872aa9cd1dfb969dc06fcb68e887554c89493a0d312f24ef88547
- document type
- citation
- dois
- 10.1002/cncr.28334
- electronic publication date
- display
- 2013 Sep 4
- precision
- day
- year
- 2013
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:24006085
- immutable id
- pubmed:24006085@b6aa87513ba872aa9cd1dfb969dc06fcb68e887554c89493a0d312f24ef88547
- journal
- abbreviation
- Cancer
- issn electronic
- 1097-0142
- issn print
- 0008-543X
- issue
- 22
- name
- Cancer
- nlm unique id
- 0374236
- pages
- 4036-43
- volume
- 119
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 24006085
- provenance
- batch id
- 0a08f044391426feb8ef
- provider
- NCBI PubMed ESummary
- record sha256
- 0dfa99ee59e5b31c897dbd3ec947a367098a6dcf4570ee7e21e720495090420f
- response sha256
- d94e6242343e5962374663e5e5f0191e7b595329228d2e360db95a280e588409
- retrieved at
- 2026-09-09T23:46:57.614689+00:00
- publication date
- display
- 2013 Nov 15
- precision
- day
- year
- 2013
- publication types
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
Preserved source evidence · Not medical advice